Document is current
Any future updates will be listed below
-
Authors
Wagner, Jannik T. http://orcid.org/0000-0002-5882-848X
Müller-Schmucker, Sandra M.
Wang, Wenjun
Arnold, Philipp
Uhlig, Nadja http://orcid.org/0000-0002-7407-0955
Issmail, Leila http://orcid.org/0000-0002-4767-1560
Eberlein, Valentina http://orcid.org/0009-0000-4541-9903
Damm, Dominik
Roshanbinfar, Kaveh http://orcid.org/0000-0001-6067-5585
Ensser, Armin
Oltmanns, Friederike
Peter, Antonia Sophia http://orcid.org/0000-0001-9667-2247
Temchura, Vladimir
Schrödel, Silke
Engel, Felix B. http://orcid.org/0000-0003-2605-3429
Thirion, Christian
Grunwald, Thomas
Wuhrer, Manfred http://orcid.org/0000-0002-0814-4995
Grimm, Dirk http://orcid.org/0000-0001-6227-5665
Überla, Klaus http://orcid.org/0000-0001-7822-3835
-
Funding
Funding for this research was provided by:
Bayerische Forschungsstiftung (AZ-1458-20)
Deutsche Forschungsgemeinschaft (Ue45/23-1, 326998133- TRR 225 subproject C01)
- License Information
-
More Information
Article History
Received: 17 November 2023
Accepted: 2 July 2024
First Online: 16 July 2024
Competing interests
: D.G. has filed a patent application on the myotropic AAV capsid; S.S. and C.T. are employees of the company Revvity Gene Delivery GmbH offering vector production services. The remaining authors declare no competing interests.
